Healthcare player, Zydus Cadila (Cadila Healthcare), on Thursday reported consolidated net profit of Rs 391 crore for the second quarter ended September 2015, up by 41 per cent from Rs 278 crore reported in the corresponding quarter last year.
The company's total operating income stood at Rs 2,460 crore, up by 17 per cent from Rs 2,108 crore in the corresponding quarter of the previous year on a consolidated basis, a company statement informed here.
During the quarter, the company’s business in the US posted sales of Rs 1,004 crore registering a growth of 25 per cent. The company received approval for 1 new product from the USFDA and 2 products were launched in the US market.
In the domestic formulations market, the company launched 13 new products, including line extensions, of which 4 products were the first to be launched in India. In Mexico, the company launched 2 new products during the quarter, taking the cumulative launches to over 15 and received the regulatory approval for 6 more dossiers, taking the cumulative number of approvals to over 30, the company said.